HomeESPR • NASDAQ
add
Esperion Therapeutics Inc
Previous close
$3.95
Day range
$3.88 - $4.02
Year range
$0.69 - $4.02
Market cap
949.08M USD
Avg Volume
6.55M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 87.31M | 69.10% |
Operating expense | 41.85M | 4.69% |
Net income | -31.33M | -6.13% |
Net profit margin | -35.89 | 37.23% |
Earnings per share | -0.16 | -6.67% |
EBITDA | -9.93M | 37.92% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 92.45M | -36.12% |
Total assets | 364.02M | 15.89% |
Total liabilities | 815.38M | 19.15% |
Total equity | -451.36M | — |
Shares outstanding | 237.07M | — |
Price to book | -1.80 | — |
Return on assets | -7.00% | — |
Return on capital | -15.84% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -31.33M | -6.13% |
Cash from operations | -4.29M | 87.87% |
Cash from investing | — | — |
Cash from financing | 10.67M | 217.34% |
Net change in cash | 6.39M | 114.32% |
Free cash flow | 3.71M | 109.69% |
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Website
Employees
304
